FDMT 주식 개요 임상 단계의 바이오 치료제 회사인 4D Molecular Therapeutics는 네덜란드와 미국에서 치료 벡터 진화 플랫폼을 사용하여 유전자 의약품을 개발하는 회사입니다. 자세한 내용
{"enabled":false,"variant":{"name":"disabled","enabled":false},"ready":false,"error":null}
생각, 링크 및 회사 내러티브를 캡처하세요.
4D Molecular Therapeutics, Inc. 경쟁사 가격 내역 및 성능
다음에 대한 주가 최고가, 최저가 및 변동 요약 4D Molecular Therapeutics 과거 주가 현재 주가 US$4.55 52주 최고치 US$36.25 52주 최저치 US$4.41 베타 2.79 1개월 변경 -4.41% 3개월 변경 사항 -43.27% 1년 변경 사항 -83.64% 3년 변화 -69.63% 5년 변화 n/a IPO 이후 변화 -88.77%
최근 뉴스 및 업데이트 더 많은 업데이트 보기
New minor risk - Share price stability Feb 03
New major risk - Revenue and earnings growth Jan 12
4D Molecular Therapeutics, Inc. Announces Strategically Focused Pipeline, Updated Phase 3 4Front Program Plans Jan 11
4Dmt Announces Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVS Dec 17
Companies Like 4D Molecular Therapeutics (NASDAQ:FDMT) Are In A Position To Invest In Growth Nov 24
Price target decreased by 8.7% to US$45.64 Nov 21
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Nov 14
4D Molecular Therapeutics: Market Expects Wet AMD Gene Therapy Failure - I'm Not So Sure Oct 04
New major risk - Revenue and earnings growth Sep 23
New major risk - Share price stability Sep 20
4D Molecular Therapeutics Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4Front Phase 3 Program At 4D-150 Wet AMD Development Day Sep 19
4D Molecular Therapeutics (NASDAQ:FDMT) Is In A Good Position To Deliver On Growth Plans Aug 10
Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Aug 09 4D Molecular Therapeutics, Inc. Announces Management Changes
4D Molecular Therapeutics: R100 Vector Pushes Forward To Bring Q4 Of 2024 DME Data Jul 19
4D Molecular Therapeutics, Inc. Announces Initial Interim 24-Week Data from the Population Extension Cohort of Its Phase 2 Clinical Trial Jul 17
Co-Founder notifies of intention to sell stock Jul 12
Co-Founder notifies of intention to sell stock Jun 27
4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic Atrophy Jun 24
4D Molecular Therapeutics Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis At 47Th European Cystic Fibrosis Conference Jun 08
First quarter 2024 earnings released: US$0.66 loss per share (vs US$0.88 loss in 1Q 2023) May 10
4D Molecular Therapeutics: Catalysts With Pioneering Gene Therapy With Directed Evolution Apr 29
New major risk - Shareholder dilution Apr 11
4D Molecular Therapeutics, Inc., Annual General Meeting, May 21, 2024 Apr 11
Insider notifies of intention to sell stock Apr 03
New major risk - Revenue and earnings growth Apr 01
Price target increased by 9.3% to US$54.75 Apr 01
4Dmt Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis Mar 29
Consensus revenue estimates decrease by 33%, EPS upgraded Mar 07
Full year 2023 earnings: EPS and revenues miss analyst expectations Mar 01
4D Molecular Therapeutics, Inc. Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024 Feb 13
Chief Medical Officer exercised options and sold US$354k worth of stock Feb 10
New major risk - Shareholder dilution Feb 07 4D Molecular Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $299.999626 million. Feb 07
4D Molecular Therapeutics Advances Wet AMD Treatment Paradigm Feb 06 4D Molecular Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million. Feb 06
New major risk - Share price stability Feb 06
Price target increased by 9.6% to US$37.00 Feb 05
4D Molecular Therapeutics Presents Positive Interim Data from Randomized Phase 2 Prism Clinical Trial of Intravitreal 4D-150 Feb 05
Co-Founder notifies of intention to sell stock Jan 25
4D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024 Jan 25
Co-Founder notifies of intention to sell stock Jan 07
4D Molecular Therapeutics Highlights Recent Clinical Pipeline Progress, Near-Term Milestones and Organizational Updates Jan 05
4D Molecular Therapeutics, Inc. Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for 4D-150 Genetic Medicine for Intravitreal Treatment of Wet AMD, the First RMAT Designation in Wet AMD Dec 21
Co-Founder notifies of intention to sell stock Dec 18
Insufficient new directors Dec 01
Consensus revenue estimates increase by 96% Nov 16
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Reported And Analysts Have Been Cutting Their Estimates Nov 12
Third quarter 2023 earnings: EPS and revenues exceed analyst expectations Nov 10
We're Not Very Worried About 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate Nov 08
4D Molecular Therapeutics Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Cystic Fibrosis At 2023 NACFC Nov 02
4D Molecular Therapeutics, Inc. Announced Alignment with the U.S. Food and Drug Administration on A Plan to Lift the Clinical Hold on the Phase 1/2 Inglaxa Clinical Trial in the United States Oct 31 4D Molecular Therapeutics, Inc. Announces Executive Changes
Price target decreased by 14% to US$33.50 Sep 12
4D Molecular Therapeutics, Inc. Announces First Patient Enrolled in 4D-150 Phase 2 Spectra Clinical Trial in DME, and Expansion of 4D-150 Phase 2 Stage in Prism Clinical Trial in Wet AMD Sep 08
Consensus revenue estimates increase by 41% Aug 16
Second quarter 2023 earnings: EPS and revenues miss analyst expectations Aug 10
4DMT Presents Additional Positive Interim Data from Intravitreal 4D-150 Phase 1/2 Prism Clinical Trial in Patients with Wet AMD at ASRS 2023 Jul 30
Consensus revenue estimates increase by 163% Jul 13
4D Molecular Therapeutics Presents Positive Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial in Patients with Cystic Fibrosis at ECFS 46th Annual Meeting Jun 08
4Dmt to Present Interim Data from 4D-710 Phase 1/2 Aerow Clinical Trial for Cystic Fibrosis Lung Disease At the European Cystic Fibrosis Society (Ecfs) 46Th Annual Meeting May 25
First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind May 12
Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation May 08
Price target increased by 8.3% to US$41.17 May 05
Full year 2022 earnings: EPS and revenues miss analyst expectations Mar 16
4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-150 Genetic Medicine for the Treatment of Diabetic Macular Edema Feb 03
Price target increased by 8.1% to US$38.00 Jan 30
4D Molecular Therapeutics, Inc. Announces Updates on Clinical Pipeline and Additional Preclinical Programs Jan 11
4D Molecular Therapeutics, Inc. Announces Updates on Clinical Pipeline and Additional Preclinical Programs Jan 10
Co-Founder notifies of intention to sell stock Dec 22
Insider exercised options and sold US$85k worth of stock Dec 06
Price target increased to US$23.80 Nov 16
High number of new directors Nov 16
4D Molecular Therapeutics, Inc. Announces Interim Clinical Data from On-Going Phase 1/2 Clinical Trial of Intravitreal 4D-150 for Wet Age-Related Macular Degeneration Nov 15
4D Molecular Therapeutics Interim Clinical Data from the On-going Phase 1/2 Clinical Trial of 4D-150 for Wet AMD to be Released November 14, 2022 Nov 11
Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 09
4D Molecular Therapeutics, Inc. Announces Interim Clinical Data from Phase 1/2 Clinical Trial of 4D-710 for Cystic Fibrosis Lung Disease At NACFC 2022 Nov 04
High number of new directors Nov 01
High number of new directors Oct 02
We're Keeping An Eye On 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate Sep 29
4D Molecular Therapeutics Appoints Noriyuki Kasahara, MD, PhD to the Board of Directors and Promotes Fred Kamal, PhD to President and Chief Operating Officer Sep 28
Second quarter 2022 earnings: EPS and revenues miss analyst expectations Aug 12
4D Molecular Therapeutics GAAP EPS of -$0.87, revenue of $0.16M Aug 11
4D Molecular Therapeutics, Inc.(NasdaqGS:FDMT) dropped from Russell 2000 Growth Index Jun 26
Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation Jun 11
Price target decreased to US$21.00 May 28
First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind May 13
Price target decreased to US$32.00 Apr 27
4D Molecular Therapeutics, Inc., Annual General Meeting, May 23, 2022 Apr 14
4D Molecular Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-710 Apr 06
Consensus revenue estimates fall by 11% Apr 05
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Mar 29 주주 수익률 FDMT US Biotechs US 마켓 7D -25.9% -4.2% 0.2% 1Y -83.6% -3.0% 23.1%
전체 주주 수익률 보기
수익률 대 산업: FDMT 지난 1년 동안 -3 %를 반환한 US Biotechs 업계보다 저조한 성과를 냈습니다.
수익률 대 시장: FDMT 지난 1년 동안 23.1 %를 반환한 US 시장보다 저조한 성과를 냈습니다.
가격 변동성 Is FDMT's price volatile compared to industry and market? FDMT volatility FDMT Average Weekly Movement 12.3% Biotechs Industry Average Movement 11.4% Market Average Movement 5.9% 10% most volatile stocks in US Market 18.3% 10% least volatile stocks in US Market 3.0%
안정적인 주가: FDMT 의 주가는 지난 3개월 동안 US 시장과 비교해 변동성이 컸습니다.
시간에 따른 변동성: FDMT 의 주간 변동성 ( 12% )은 지난 1년 동안 안정적이었지만 여전히 US 의 75%보다 높습니다. 주식.
회사 소개 임상 단계의 바이오 치료제 회사인 4D Molecular Therapeutics는 네덜란드와 미국에서 치료 벡터 진화 플랫폼을 사용하여 유전자 의약품을 개발하는 회사입니다. 이 회사는 안과, 심장학, 폐학 등 세 가지 치료 분야에 초점을 맞춘 유전자 의약품 후보 포트폴리오를 개발하고 있습니다. 제품 파이프라인에는 습성 연령 관련 황반변성 치료를 위한 임상 1/2상 시험 중인 4D-150과 당뇨병성 황반부종 치료를 위한 임상 1/2상 시험 중인 4D-125가 있습니다.
자세히 보기 4D Molecular Therapeutics, Inc. 기본 사항 요약 4D Molecular Therapeutics 의 수익과 매출은 시가총액과 어떻게 비교하나요? FDMT 기본 통계 시가총액 US$211.72m 수익(TTM ) -US$143.48m 수익(TTM ) US$17.00k
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) FDMT 손익 계산서(TTM ) 수익 US$17.00k 수익 비용 US$124.24m 총 이익 -US$124.22m 기타 비용 US$19.26m 수익 -US$143.48m
주당 순이익(EPS) -3.10 총 마진 -730,723.53% 순이익 마진 -844,000.00% 부채/자본 비율 0%
FDMT 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기
기업 분석 및 재무 데이터 현황 데이터 마지막 업데이트(UTC 시간) 기업 분석 2025/02/12 00:13 장 마감 주가 2025/02/12 00:00 수익 2024/09/30 연간 수익 2023/12/31
데이터 소스 기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.
패키지 데이터 기간 미국 소스 예시 * 회사 재무 10년 애널리스트 컨센서스 추정치 +3년 시장 가격 30년 소유권 10년 관리 10년 주요 개발 사항 10년
* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처는 미국 증권의 예를 사용했습니다.
명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 자세히 알아보기 .
분석 모델 및 눈송이 이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.
Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.
산업 및 부문 메트릭 업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 Github에서 확인할 수 있습니다.
애널리스트 출처 4D Molecular Therapeutics, Inc. 14 애널리스트 중 8 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.
분석가 교육기관 Huidong Wang Barclays Konstantinos Biliouris BMO Capital Markets Equity Research Daniel Giraldo BofA Global Research
11 더 많은 분석가 보기 
